Your email has been successfully added to our mailing list.

×
0 0.235294117647059 0.235294117647059 0.226890756302521 0.19327731092437 0.19327731092437 0.11764705882353 0.218403361344538
Stock impact report

Spring Bank Announces Clinical Collaboration to Evaluate SB 11285 in Combination with PD-L1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors

SPRING BANK PHARMACEUTICALS (SBPH) 
Last spring bank pharmaceuticals earnings: 11/7 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.springbankpharm.com/investor-overview
Company Research Source: GlobeNewswire
HOPKINTON, Mass., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and inflammatory diseases, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore the co-administration of SB 11285, Spring Bank’s intravenously (IV)-administered STING (STimulator of INterferon Gene) agonist with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) in patients with advanced solid tumors.  During the fourth quarter of 2019, Spring Bank dosed the first patient in the monotherapy dose escalation component of the intravenously-administered SB 11285 Phase 1a trial. This monotherapy dose escalation component will be followed by a combination dose escalation of IV SB 11285 with a checkpoint inhibitor (nivolumab) and with atezolizumab (Tecentriq®) as an additional arm added to the combination dose escalation segment of the Phase 1a trial. By the end of Show less Read more
Impact Snapshot
Event Time:
SBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for SBPH alerts
Opt-in for
SBPH alerts

from News Quantified
Opt-in for
SBPH alerts

from News Quantified